An interspecies translation model implicates integrin signaling in infliximab-resistant inflammatory bowel disease.

ABSTRACT: Anti-tumor necrosis factor (anti-TNF) therapy resistance is a major clinical challenge in inflammatory bowel disease (IBD), due, in part, to insufficient understanding of disease-site, protein-level mechanisms. Although proteomics data from IBD mouse models exist, data and phenotype discrepancies contribute to confounding translation from preclinical animal models of disease to clinical cohorts. We developed an approach called translatable components regression (TransComp-R) to overcome interspecies and trans-omic discrepancies between mouse models and human subjects. TransComp-R combines mouse proteomic data with patient pretreatment transcriptomic data to identify molecular features discernable in the mouse data that are predictive of patient response to therapy. Interrogating the TransC

SUBMITTER: Brubaker DK 

PROVIDER: S-EPMC7459361 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature